Recurrent KRAS codon 146 mutations in human colorectal cancer

Cancer Biology and Therapy

Volumn 5, Issue 8, 2006, Pages 928-932

  Edkins, Sarah ^a   O'Meara, Sarah ^a   Parker, Adrian ^a   Stevens, Claire ^a   Reis, Marcelo ^b   Jones, Siân ^b   Greenman, Chris ^a   Davies, Helen ^a   Dalgliesh, Gillian ^a   Forbes, Simon ^a   Hunter, Chris ^a   Smith, Raffaella ^a   Stephens, Philip ^a   Goldstraw, Peter ^c   Nicholson, Andrew ^c   Tsun, Leung Chan ^d   Velculescu, Victor E ^b   Siu, Tsan Yuen ^d   Suet, Yi Leung ^d   Stratton, Michael R ^a,e   Futreal, P Andrew ^a   more..

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

A146; Cancer; Colorectal; KRAS; Mutation

Indexed keywords

ALANINE; GUANINE NUCLEOTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CODON; COLORECTAL CANCER; GENE MUTATION; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS;

EID: 33751165545     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.8.3251     Document Type: Article

References (21)

1. Tabin C, Bradley S, Bargmann C, Weinberg R, Papageorge A, Scolnick E, Dhar R, Lowy D, Chang E. Mechanism of activation of a human oncogene. Nature 1982; 300:143-9.
2. Reddy E, Reynolds R, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982; 300:149-52.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.
4. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JKV, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300:949.
5. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O'Meara S, Avis T, Barthorpe S, Brackenbury L, Buck G, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LHJ, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005; 65:7591-5.
6. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62:6451-5.
7. Naoko H, Sachiko S, Isao I, Shoji N, Michio O, Yusuke N. Ethnic difference in the pattern of K-ras oncogene mutations in human colorectal cancers. Human Mutation 1996; 8:258-61.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
9. DeMarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: A review. Mutation Research/Reviews in Mutation Research 2004; 567:447-74.
10. Kakunaga T. Neoplastic transformation of human diploid fibroblast cells by chemical carcinogens. PNAS 1978; 75:1334-8.
11. McCormick J, Yang D, Maher V, Farber R, Neuman W, Peterson W, Pollack M. The HuT series of 'carcinogen-transformed' human fibroblast cell lines are derived from the human fibrosarcoma cell line 8387. Carcinogenesis 1988; 9:2073-9.
12. Orita S, Higashi T, Kawasaki Y, Harada A, Igarashi H, Monden T, Morimoto H, Shimano T, Mori T, Miyoshi J. A novel point mutation at codon 146 of the K-ras gene in a human colorectal cancer identified by the polymerase chain reaction. Virus Genes 1991; 5:75-9.
13. Sloan SR, Newcomb EW, Pellicer A. Neutron radiation can activate K-ras via a point mutation in codon 146 and induces a different spectrum of ras mutations than does gamma radiation. Mol Cell Biol 1990; 10:405-8.
14. Feig LA, Cooper GM. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol 1988; 8:2472-8.
15. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 2001; 294:1299-304.
16. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. British Journal of Cancer 2001; 85:692-6.
17. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13:1438-46.
18. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJC. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma 0.1136/gut.2005.066514. Gut 2005; 54:1283-6.
19. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19:299-304.
20. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5.
21. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358-62.